AstraZeneca ((AZN)), Icon Plc ((ICLR)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The MaesTTRo study, officially titled ‘A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis,’ aims to collect comprehensive data on patients with ATTR amyloidosis. This study seeks to understand the natural progression of the disease and evaluate treatment patterns and outcomes, particularly focusing on the effectiveness of treatments like eplontersen.
The intervention being tested is a drug treatment for transthyretin (ATTR) amyloidosis, observed in a real-world setting. Eplontersen, a ligand-conjugated antisense oligonucleotide, targets both mutant and wild-type TTR proteins to manage the disease.
The study is observational with a cohort model and a prospective time perspective. It involves collecting primary data through patient-reported outcome questionnaires and secondary data from clinical records, without requiring additional site visits.
The study began on June 25, 2024, with primary completion expected in several years, given the enrollment period of approximately four years and follow-up lasting up to seven years. The latest update was submitted on August 4, 2025, indicating ongoing recruitment.
This study could significantly impact AstraZeneca’s market position by potentially validating the effectiveness of eplontersen, thus influencing investor sentiment positively. As the study progresses, it may also affect the competitive landscape in the treatment of ATTR amyloidosis.
The MaesTTRo study is currently ongoing, with further details available on the ClinicalTrials portal.